Drugs / Fluorescite
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FLUORESCITE | — | 2006-03-28 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03189134 | Apr 2018 → Mar 2019 | atrial septal defect | Aditya Kaza | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04017975 | Dec 2019 → Sep 2023 overdue | complete atrioventricular canal, tetralogy of fallot, ventricular septal defect | Aditya Kaza | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorescite | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04017975 ↗ |
| Route | Topical | “will be applied topically to the cardiac tissue” NCT04017975 ↗ |